Earnings summaries and quarterly performance for WW INTERNATIONAL.
Executive leadership at WW INTERNATIONAL.
Board of directors at WW INTERNATIONAL.
Research analysts who have asked questions during WW INTERNATIONAL earnings calls.
AF
Alex Fuhrman
Craig-Hallum Capital Group LLC
5 questions for WW
Also covers: APYX, ATER, BNED +21 more
Nathaniel Feather
Morgan Stanley
5 questions for WW
Also covers: BMBL, CHWY, DUOL +6 more
Henry Carr
UBS
3 questions for WW
Karru Martinson
Jefferies
3 questions for WW
Also covers: ARKO, BGS, HLF +1 more
JW
Jack Wallace
Guggenheim Partners
2 questions for WW
Also covers: ACCD, AMWL, PHR +1 more
ML
Michael Lasser
UBS
2 questions for WW
Also covers: AAP, ASO, AZO +24 more
SD
Stephanie Davis
Barclays
2 questions for WW
Also covers: ACCD, CAH, COR +20 more
LB
Linda Bolton-Weiser
D.A. Davidson & Co.
1 question for WW
Also covers: CLX, ELF, FLWS +14 more
Recent press releases and 8-K filings for WW.
WW Reports Q3 2025 Results with Revenue Decline and Strategic Shift to Clinical Offerings
WW
Earnings
New Projects/Investments
Demand Weakening
- Weight Watchers International reported Q3 2025 revenue of $172 million, an 11% decline year-over-year, with adjusted EBITDA of $43 million and an adjusted EBITDA margin of 24.9%.
- The company experienced a significant shift in its subscriber base, with clinical subscribers growing 60% year-over-year to 124,000, while behavioral subscribers declined 20% year-over-year to 2.9 million. Clinical revenue increased 35% year-over-year.
- WW is undergoing a digital transformation, with modernized app and website iterations expected for peak season early next year, and has launched a Weight Watchers for Menopause program.
- The company successfully transitioned approximately 20% of its compounded GLP-1 members to ongoing clinical programs, exceeding expectations, and anticipates Q3 2025 was the low point for clinical subscribers.
- Management expects Q4 adjusted EBITDA to decline compared to Q3 due to increased marketing investment and projects 2026 capital expenditures to return toward historical levels.
Nov 6, 2025, 1:30 PM
WW International, Inc. Announces Third Quarter 2025 Results
WW
Earnings
Guidance Update
New Projects/Investments
- WW International, Inc. reported Q3 2025 total revenues of $172 million and a net loss of $58 million, with an Adjusted EBITDA of $43 million and an Adjusted EBITDA Margin of 24.9%.
- Clinical Subscription Revenues grew 35% year-over-year to $26 million, contributing to the 3.0 million total subscribers, which includes 124 thousand clinical subscribers.
- The company significantly strengthened its balance sheet post-restructuring, reducing total debt by over 70% (approximately $1.1 billion) and increasing cash to $170 million at quarter-end.
- Full-year fiscal 2025 guidance was narrowed to the higher end of previous ranges, with revenues expected between $695 million and $700 million and Adjusted EBITDA between $145 million and $150 million.
- Strategic focus remains on integrating medical innovation (GLP-1s) with behavioral science, launching initiatives like the new Menopause program, and expanding medical offerings.
Nov 6, 2025, 12:05 PM
Quarterly earnings call transcripts for WW INTERNATIONAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more